Insulin-sensitive Obesity: Lessons From Longitudinal Data (ISOS)
|ClinicalTrials.gov Identifier: NCT02017210|
Recruitment Status : Completed
First Posted : December 20, 2013
Last Update Posted : March 7, 2017
People who are overweight and/or obese usually are insulin resistant and so are at risk of type 2 diabetes. However, research has shown that some overweight and/or obese people remain insulin sensitive and healthy despite their weight.
The investigators hypothesise that insulin-sensitive overweight and/or obese people maintain their insulin sensitivity and metabolic health over time. The investigators also hypothesise that the preservation of insulin sensitivity will be determined by key metabolic factors.
|Condition or disease||Intervention/treatment|
|Insulin Sensitivity/Resistance Obesity Weight Loss||Other: Longitudinal study|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||68 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Insulin-sensitive Obesity: Prospective and Interventional Studies|
|Study Start Date :||November 2013|
|Primary Completion Date :||February 2016|
|Study Completion Date :||February 2016|
Experimental: Longitudinal follow up
Participant's metabolic parameters are followed up after approximately 6 years.
Other: Longitudinal study
Metabolic health, anthropometry, body fat distribution, liver lipid will be followed up in individuals previously studied at the Clinical Research Facility.
- Change in insulin sensitivity [ Time Frame: change in insulin sensitivity at follow up compared to 6 years ago ]Insulin sensitivity will be assessed in this current follow up study. This will be compared to insulin sensitivity data collected in this study cohort approximately 6 years ago.
- Change in anthropometry (weight, height, BMI, waist and hip circumference) [ Time Frame: Change at follow up compared to 6 years ago ]
- Change in total body fat and distribution [ Time Frame: Change at follow up compared to 6 years ago ]
- Change in fasting insulin, c-peptide, glucose levels [ Time Frame: Change at follow up compared to 6 years ago ]
- Change in HbA1c, 75g oral glucose tolerance [ Time Frame: Change at follow up compared to 6 years ago ]
- Change in fasting non-esterified fatty acids and lipids profile [ Time Frame: Change at follow up compared to 6 years ago ]
- Change in circulating adipokines, cytokines and hepatokines [ Time Frame: Change at follow up compared to 6 years ago ]
- Change in blood pressure [ Time Frame: Change at follow up compared to 6 years ago ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02017210
|Australia, New South Wales|
|Garvan Institute of Medical Research|
|Darlinghurst, New South Wales, Australia, 2010|
|Principal Investigator:||Jerry R Greenfield, BSc(Med) MBBS PhD FRACP||Garvan Institute of Medical Research|
|Principal Investigator:||Dorit Samocha-Bonet, BSc(Hons) MSc(Hons) PhD||Garvan Institute of Medical Research|